Observation Versus Treatment in Men with Prostate Cancer

Video

Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men’s treatment decisions after seeing a rise in their PSA levels. <

Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men&rsquo;s treatment decisions after seeing a rise in their PSA levels.

Clinical Pearls:

  • One of the studies presented at the 2014 ASCO Annual Meeting reviewed data of men who decided to wait or pursue treatment.
  • Results of this study showed there was no difference in survival regardless of their decision.
  • Men and doctors can now better discuss remaining on observation or starting treatment.
Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content